Hadrien Lanvin; Anna Kostrzak, PhD; Amanda Brun, PhD, PharmD, CSO
Competition Sponsor: EIT Health of the European Union
EVORA develops EVOGEX, a breakthrough treatment of complex digestive fistulas (GI). EVORA uses stem cells to secrete biological nanoparticles called exosomes, which are the “active principle” at the core of EVOGEX. Exosomes are a much more industry-friendly alternative to conventional cell therapy, where stem cells are directly administered to patients. Indeed, exosomes can be produced at scale, have significant logistics advantages, and retain and can sometimes supersede the therapeutic properties of stem cells. We believe exosomes are where cell therapy is headed and will become a major therapeutic platform in the coming years, for regenerative medicine and beyond.